Clinical grade OK432-activated dendritic cells: In vitro characterization and tracking during intralymphatic delivery

Emma West, Ruth Morgan, Karen Scott, Alison Merrick, Anatole Lubenko, David Pawson, Peter Selby, Paul Hatfield, Robin Prestwich, Sheila Fraser, David Eves, Alan Anthoney, Chris Twelves, Debbie Beirne, Poulam Patel, Dearbhaile Odonnell, Suzanne Watt, Michael Waller, Allan B Dietz, Philip RobinsonAlan Melcher

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Dendritic cells (DC) are under intense preclinical and early clinical evaluation for the immunotherapy of cancer. However, the optimal culture conditions and route of delivery for DC vaccination have not been established. Here we describe the first human application of DC matured with the bacterial agent OK432 (OK-DC), using a short-term serum-free culture protocol, which generates mature DC from CD14 precursors after 5 days. These cells were prepared within the framework of a National Blood Service facility, demonstrating that DC represent a product which is potentially deliverable alongside current standardized cell therapies within the UK National Health Service. In vitro analysis confirmed that OK-DC were mature, secreted tumor necrosis factor-α, interleukin-6, and interleukin-12, and stimulated both T cell and natural killer cell function. To explore effective delivery of OK-DC to lymph nodes, we performed an initial clinical tracking study of radioactively labeled, unpulsed OK-DC after intralymphatic injection into the dorsum of the foot. We showed that injected DC rapidly localized to ipsilateral pelvic lymph nodes, but did not disseminate to more distant nodes over a 48-hour period. There was no significant toxicity associated with OK-DC delivery. These results show that OK-DC are suitable for clinical use, and that intralymphatic delivery is feasible for localizing cells to sites where optimal priming of innate and adaptive antitumor immunity is likely to occur.

Original languageEnglish (US)
Pages (from-to)66-78
Number of pages13
JournalJournal of Immunotherapy
Volume32
Issue number1
DOIs
StatePublished - Jan 2009

Fingerprint

Dendritic Cells
Intralymphatic Injections
In Vitro Techniques
Lymph Nodes
National Health Programs
Adaptive Immunity
Interleukin-12
Cell- and Tissue-Based Therapy
Natural Killer Cells
Immunotherapy
Foot
Interleukin-6
Vaccination
Tumor Necrosis Factor-alpha
T-Lymphocytes

Keywords

  • Dendritic cells
  • Intralymphatic delivery
  • NK cells
  • OK432
  • T cells

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Cancer Research
  • Pharmacology
  • Medicine(all)

Cite this

Clinical grade OK432-activated dendritic cells : In vitro characterization and tracking during intralymphatic delivery. / West, Emma; Morgan, Ruth; Scott, Karen; Merrick, Alison; Lubenko, Anatole; Pawson, David; Selby, Peter; Hatfield, Paul; Prestwich, Robin; Fraser, Sheila; Eves, David; Anthoney, Alan; Twelves, Chris; Beirne, Debbie; Patel, Poulam; Odonnell, Dearbhaile; Watt, Suzanne; Waller, Michael; Dietz, Allan B; Robinson, Philip; Melcher, Alan.

In: Journal of Immunotherapy, Vol. 32, No. 1, 01.2009, p. 66-78.

Research output: Contribution to journalArticle

West, E, Morgan, R, Scott, K, Merrick, A, Lubenko, A, Pawson, D, Selby, P, Hatfield, P, Prestwich, R, Fraser, S, Eves, D, Anthoney, A, Twelves, C, Beirne, D, Patel, P, Odonnell, D, Watt, S, Waller, M, Dietz, AB, Robinson, P & Melcher, A 2009, 'Clinical grade OK432-activated dendritic cells: In vitro characterization and tracking during intralymphatic delivery', Journal of Immunotherapy, vol. 32, no. 1, pp. 66-78. https://doi.org/10.1097/CJI.0b013e31818be071
West, Emma ; Morgan, Ruth ; Scott, Karen ; Merrick, Alison ; Lubenko, Anatole ; Pawson, David ; Selby, Peter ; Hatfield, Paul ; Prestwich, Robin ; Fraser, Sheila ; Eves, David ; Anthoney, Alan ; Twelves, Chris ; Beirne, Debbie ; Patel, Poulam ; Odonnell, Dearbhaile ; Watt, Suzanne ; Waller, Michael ; Dietz, Allan B ; Robinson, Philip ; Melcher, Alan. / Clinical grade OK432-activated dendritic cells : In vitro characterization and tracking during intralymphatic delivery. In: Journal of Immunotherapy. 2009 ; Vol. 32, No. 1. pp. 66-78.
@article{c1bb422ccbf540bfb57c13912d157f34,
title = "Clinical grade OK432-activated dendritic cells: In vitro characterization and tracking during intralymphatic delivery",
abstract = "Dendritic cells (DC) are under intense preclinical and early clinical evaluation for the immunotherapy of cancer. However, the optimal culture conditions and route of delivery for DC vaccination have not been established. Here we describe the first human application of DC matured with the bacterial agent OK432 (OK-DC), using a short-term serum-free culture protocol, which generates mature DC from CD14 precursors after 5 days. These cells were prepared within the framework of a National Blood Service facility, demonstrating that DC represent a product which is potentially deliverable alongside current standardized cell therapies within the UK National Health Service. In vitro analysis confirmed that OK-DC were mature, secreted tumor necrosis factor-α, interleukin-6, and interleukin-12, and stimulated both T cell and natural killer cell function. To explore effective delivery of OK-DC to lymph nodes, we performed an initial clinical tracking study of radioactively labeled, unpulsed OK-DC after intralymphatic injection into the dorsum of the foot. We showed that injected DC rapidly localized to ipsilateral pelvic lymph nodes, but did not disseminate to more distant nodes over a 48-hour period. There was no significant toxicity associated with OK-DC delivery. These results show that OK-DC are suitable for clinical use, and that intralymphatic delivery is feasible for localizing cells to sites where optimal priming of innate and adaptive antitumor immunity is likely to occur.",
keywords = "Dendritic cells, Intralymphatic delivery, NK cells, OK432, T cells",
author = "Emma West and Ruth Morgan and Karen Scott and Alison Merrick and Anatole Lubenko and David Pawson and Peter Selby and Paul Hatfield and Robin Prestwich and Sheila Fraser and David Eves and Alan Anthoney and Chris Twelves and Debbie Beirne and Poulam Patel and Dearbhaile Odonnell and Suzanne Watt and Michael Waller and Dietz, {Allan B} and Philip Robinson and Alan Melcher",
year = "2009",
month = "1",
doi = "10.1097/CJI.0b013e31818be071",
language = "English (US)",
volume = "32",
pages = "66--78",
journal = "Journal of Immunotherapy",
issn = "1053-8550",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Clinical grade OK432-activated dendritic cells

T2 - In vitro characterization and tracking during intralymphatic delivery

AU - West, Emma

AU - Morgan, Ruth

AU - Scott, Karen

AU - Merrick, Alison

AU - Lubenko, Anatole

AU - Pawson, David

AU - Selby, Peter

AU - Hatfield, Paul

AU - Prestwich, Robin

AU - Fraser, Sheila

AU - Eves, David

AU - Anthoney, Alan

AU - Twelves, Chris

AU - Beirne, Debbie

AU - Patel, Poulam

AU - Odonnell, Dearbhaile

AU - Watt, Suzanne

AU - Waller, Michael

AU - Dietz, Allan B

AU - Robinson, Philip

AU - Melcher, Alan

PY - 2009/1

Y1 - 2009/1

N2 - Dendritic cells (DC) are under intense preclinical and early clinical evaluation for the immunotherapy of cancer. However, the optimal culture conditions and route of delivery for DC vaccination have not been established. Here we describe the first human application of DC matured with the bacterial agent OK432 (OK-DC), using a short-term serum-free culture protocol, which generates mature DC from CD14 precursors after 5 days. These cells were prepared within the framework of a National Blood Service facility, demonstrating that DC represent a product which is potentially deliverable alongside current standardized cell therapies within the UK National Health Service. In vitro analysis confirmed that OK-DC were mature, secreted tumor necrosis factor-α, interleukin-6, and interleukin-12, and stimulated both T cell and natural killer cell function. To explore effective delivery of OK-DC to lymph nodes, we performed an initial clinical tracking study of radioactively labeled, unpulsed OK-DC after intralymphatic injection into the dorsum of the foot. We showed that injected DC rapidly localized to ipsilateral pelvic lymph nodes, but did not disseminate to more distant nodes over a 48-hour period. There was no significant toxicity associated with OK-DC delivery. These results show that OK-DC are suitable for clinical use, and that intralymphatic delivery is feasible for localizing cells to sites where optimal priming of innate and adaptive antitumor immunity is likely to occur.

AB - Dendritic cells (DC) are under intense preclinical and early clinical evaluation for the immunotherapy of cancer. However, the optimal culture conditions and route of delivery for DC vaccination have not been established. Here we describe the first human application of DC matured with the bacterial agent OK432 (OK-DC), using a short-term serum-free culture protocol, which generates mature DC from CD14 precursors after 5 days. These cells were prepared within the framework of a National Blood Service facility, demonstrating that DC represent a product which is potentially deliverable alongside current standardized cell therapies within the UK National Health Service. In vitro analysis confirmed that OK-DC were mature, secreted tumor necrosis factor-α, interleukin-6, and interleukin-12, and stimulated both T cell and natural killer cell function. To explore effective delivery of OK-DC to lymph nodes, we performed an initial clinical tracking study of radioactively labeled, unpulsed OK-DC after intralymphatic injection into the dorsum of the foot. We showed that injected DC rapidly localized to ipsilateral pelvic lymph nodes, but did not disseminate to more distant nodes over a 48-hour period. There was no significant toxicity associated with OK-DC delivery. These results show that OK-DC are suitable for clinical use, and that intralymphatic delivery is feasible for localizing cells to sites where optimal priming of innate and adaptive antitumor immunity is likely to occur.

KW - Dendritic cells

KW - Intralymphatic delivery

KW - NK cells

KW - OK432

KW - T cells

UR - http://www.scopus.com/inward/record.url?scp=65549103031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549103031&partnerID=8YFLogxK

U2 - 10.1097/CJI.0b013e31818be071

DO - 10.1097/CJI.0b013e31818be071

M3 - Article

C2 - 19307995

AN - SCOPUS:65549103031

VL - 32

SP - 66

EP - 78

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1053-8550

IS - 1

ER -